BeOne Medicines reports Q2 2026 results, raises full-year revenue guidance
Positive MANGROVE data in mantle cell lymphoma, an FDA accelerated approval for BEQALZI, and a raised 2026 revenue outlook of $6.6–$6.8 billion highlight the update.
BeOne Medicines Ltd. announced second quarter 2026 results and business updates on August 5, 2026, for the quarter ended June 30, 2026.
On the pipeline side, the company achieved positive topline results from the Phase 3 MANGROVE study in combination with rituximab, demonstrating progression-free survival superiority versus bendamustine plus rituximab in adult patients with previously untreated mantle cell lymphoma.1 It also reported long-term 78-month follow-up data from the Phase 3 SEQUOIA study, showing sustained PFS benefit for treatment-naïve chronic lymphocytic leukemia, at ASCO and EHA.1
BEQALZI (sonrotoclax) received FDA accelerated approval for relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a BTK inhibitor.1 TEVIMBRA achieved Japan regulatory approval for first-line gastric cancer,1 and full Phase 3 HERIZON-GEA-01 results for ZIIHERA (zanidatamab) plus chemotherapy, with and without TEVIMBRA, versus trastuzumab plus chemotherapy in first-line HER2-positive gastroesophageal adenocarcinoma were published in the New England Journal of Medicine.1
Looking ahead, BeOne expects regulatory submissions for BRUKINSA in first-line MCL across the U.S., Europe, China and Japan in the second half of 20261, plus U.S. FDA action in the second half of 2026 and China regulatory action in the first half of 2027 for TEVIMBRA combined with ZIIHERA and chemotherapy in first-line HER2-positive gastroesophageal cancer.1
Corporately, BeOne announced a $300 million expansion of its manufacturing and R&D center at the Princeton West Innovation Campus in Hopewell, New Jersey, adding small molecule manufacturing capabilities,1 and appointed Felix J. Baker, Elizabeth F. Mooney, and Charles L. Sawyers to its board of directors.1
Financially, total global revenues were $1.7 billion for the quarter, up 30% from the prior year, with 2026 total revenue guidance raised to $6.6 to $6.8 billion.1 Cash, cash equivalents and restricted cash stood at $5,280,674 thousand as of June 30, 2026, up from $4,609,647 thousand at year-end 2025.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.